Intuitive Surgical’s Q3 2026 da Vinci procedure growth market reflects trader focus on moderating momentum amid a 13.5–15.5% full-year guidance range, following 15% da Vinci growth in Q2 and 18% for 2025. Recent U.S. trends show deceleration to around 12% in Q2, pressured by Affordable Care Act subsidy changes, larger installed-base effects, and hospital budget constraints, while international da Vinci procedures expanded 20% with strength in India and select European markets offsetting China headwinds. The da Vinci 5 platform supports utilization gains of about 11% versus prior systems and fuels general surgery and acute-care volumes, yet tougher year-ago comparisons from Q3 2025’s near-20% print and emerging competition from Johnson & Johnson’s OTTAVA system contribute to balanced probabilities across the 10–17.5% bins. Q3 results, due October 20, alongside any margin or placement commentary, represent the key near-term catalyst for shifts in these market-implied odds.